KPTI Karyopharm Therapeutics
Karyopharm Therapeutics earnings company data as of 11:01 AM ET 10/23
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 2 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 13 Aug | EPS | — | -2.32 | — |
| Rev | — | $33.4M | — |
Insider trades
Open-market buys and sales by KPTI's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- None no planned (10b5-1) sales
No open-market buys or sales on file.
Also filed in the last 12 months, not counted as buying or selling: 21 sales to cover taxes and 19 stock grants.
SEC filings
Recent issuer filings from EDGAR, 24 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 8.01 | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 3.03,5.03,9.01 | Filing Doc | |
| 8-K | 1.01,2.04,3.02,8.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 5.02,5.07,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.